A detailed history of Cubist Systematic Strategies, LLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 10,026 shares of CRVS stock, worth $48,124. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,026
Previous 24,364 58.85%
Holding current value
$48,124
Previous $44,000 18.18%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.78 - $5.92 $25,521 - $84,880
-14,338 Reduced 58.85%
10,026 $52,000
Q2 2024

Aug 14, 2024

BUY
$1.36 - $2.29 $33,135 - $55,793
24,364 New
24,364 $44,000
Q2 2023

Aug 14, 2023

BUY
$1.0 - $3.86 $15,552 - $60,030
15,552 New
15,552 $35,000
Q2 2022

Aug 15, 2022

SELL
$0.87 - $2.03 $5,742 - $13,397
-6,600 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$1.46 - $2.48 $24,301 - $41,279
-16,645 Reduced 71.61%
6,600 $11,000
Q4 2021

Feb 14, 2022

BUY
$2.34 - $5.31 $7,471 - $16,954
3,193 Added 15.92%
23,245 $56,000
Q3 2021

Nov 15, 2021

BUY
$1.89 - $8.53 $37,898 - $171,043
20,052 New
20,052 $97,000
Q4 2017

Feb 14, 2018

SELL
$9.3 - $16.93 $17,800 - $32,404
-1,914 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$11.3 - $17.23 $21,628 - $32,978
1,914
1,914 $31,000

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $223M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.